Results 1 to 10 of about 153,127 (306)

Clinical, socioeconomic, and behavioural factors at age 50 years and risk of cardiometabolic multimorbidity and mortality: A cohort study. [PDF]

PLoS Medicine, 2018
BackgroundMultimorbidity is increasingly common and is associated with adverse health outcomes, highlighting the need to broaden the single-disease framework that dominates medical research.
Archana Singh-Manoux, Aurore Fayosse, Séverine Sabia, Adam Tabak, Martin Shipley, Aline Dugravot, Mika Kivimäki   +6 more
doaj   +2 more sources

Antisense Oligonucleotide Technologies to Combat Obesity and Fatty Liver Disease

Frontiers in Physiology, 2022
Synthetic oligonucleotide technologies are DNA or RNA based molecular compounds that are utilized to disrupt gene transcription or translation in target tissues or cells. Optimally, oligonucleotides are 10–30 base pairs in length, and mediate target gene
Michael F. Keating, Michael F. Keating, Michael F. Keating, Brian G. Drew, Brian G. Drew, Brian G. Drew, Anna C. Calkin, Anna C. Calkin, Anna C. Calkin   +8 more
doaj   +1 more source

High absolute neutrophil count with type 2 diabetes is associated with adverse outcome in patients with coronary artery disease: A large-scale cohort study

Frontiers in Endocrinology, 2023
BackgroundInflammatory processes crucially modulate the development, progression, and outcomes of coronary artery disease (CAD). Since hyperglycemia could alter inflammatory responses, this study aimed to investigate the effect of ANC, a novel and ...
Jining He, Jining He, Zhangyu Lin, Zhangyu Lin, Chenxi Song, Chenxi Song, Rui Zhang, Rui Zhang, Haoyu Wang, Haoyu Wang, Sheng Yuan, Sheng Yuan, Xiaohui Bian, Xiaohui Bian, Qiuting Dong, Kefei Dou, Kefei Dou   +16 more
doaj   +1 more source

Coronavirus Disease 2019 and Cardiometabolic Disease

Cardiology in Review, 2021
Cardiometabolic disease describes a combination of metabolic abnormalities that increases the risk of type 2 diabetes and cardiovascular diseases, including pathological changes such as insulin resistance, hyperglycemia, dyslipidemia, abdominal obesity, and hypertension, and environmental risk factors such as smoking, sedentary lifestyle, poor diet ...
Chan W, Kim, Wilbert S, Aronow, William H, Frishman   +2 more
openaire   +3 more sources

Circulating Microbiota in Cardiometabolic Disease

Frontiers in Cellular and Infection Microbiology, 2022
The rapid expansion of microbiota research has significantly advanced our understanding of the complex interactions between gut microbiota and cardiovascular, metabolic, and renal system regulation. Low-grade chronic inflammation has long been implicated as one of the key mechanisms underlying cardiometabolic disease risk and progression, even before ...
Keiichi Sumida, Zhongji Han, Chi-Yang Chiu, Tahliyah S. Mims, Amandeep Bajwa, Ryan T. Demmer, Ryan T. Demmer, Susmita Datta, Csaba P. Kovesdy, Csaba P. Kovesdy, Joseph F. Pierre   +10 more
openaire   +3 more sources

The value of the MIND diet in the primary and secondary prevention of hypertension: A cross-sectional and longitudinal cohort study from NHANES analysis

Frontiers in Nutrition, 2023
BackgroundThe Mediterranean-Dietary Approaches to Stop Hypertension for neurodegenerative delay (MIND) has been regarded as a novel healthy dietary pattern with huge benefits.
Yanjun Song, Yanjun Song, Yanjun Song, Zhen'ge Chang, Kongyong Cui, Kongyong Cui, Kongyong Cui, Chenxi Song, Chenxi Song, Chenxi Song, Zhongxing Cai, Zhongxing Cai, Zhongxing Cai, Boqun Shi, Boqun Shi, Boqun Shi, Qiuting Dong, Qiuting Dong, Qiuting Dong, Kefei Dou, Kefei Dou, Kefei Dou   +21 more
doaj   +1 more source

VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosis

mAbs, 2020
CX3CR1 has been identified as a highly attractive target for several therapeutic interventions. Despite this potential, no potent antagonists, either small molecule or monoclonal antibody, have been identified.
Sarah Low, Haixia Wu, Kavita Jerath, Annette Tibolla, Birgit Fogal, Rebecca Conrad, Deborah Webb, Margit MacDougall, Steven Kerr, Valentina Berger, Rajvee Dave, Jorge Villalona, Lynn Pantages, Jennifer Ahlberg, Hua Li, Diane Van Hoorick, Cedric Ververken, John Broadwater, Alisa Waterman, Sanjaya Singh, Rachel Kroe-Barrett   +20 more
doaj   +1 more source

Modulation of myosin by cardiac myosin binding protein-C peptides improves cardiac contractility in ex-vivo experimental heart failure models

Scientific Reports, 2022
Cardiac myosin binding protein-C (cMyBP-C) is an important regulator of sarcomeric function. Reduced phosphorylation of cMyBP-C has been linked to compromised contractility in heart failure patients.
Luqia Hou, Mohit Kumar, Priti Anand, Yinhong Chen, Nesrine El-Bizri, Chad J. Pickens, W. Michael Seganish, Sakthivel Sadayappan, Gayathri Swaminath   +8 more
doaj   +1 more source

Lipoprotein(a) and Cardiovascular Outcomes in Patients With Coronary Artery Disease and Different Metabolic Phenotypes

Frontiers in Cardiovascular Medicine, 2022
BackgroundThe positive relationship between metabolic healthy obesity (MHO) and cardiovascular risk has been under debate in recent years. Previously, strong evidence supported the causal role of increased plasma lipoprotein(a) [Lp(a)] levels in ...
Jing-Lu Jin, Jing-Lu Jin, Hui-Wen Zhang, Hui-Hui Liu, Cheng-Gang Zhu, Yuan-Lin Guo, Na-Qiong Wu, Rui-Xia Xu, Qian Dong, Jian-Jun Li   +9 more
doaj   +1 more source

Inflammatory markers and cardiometabolic diseases [PDF]

Acta Clinica Belgica, 2015
A growing body of evidence emerges that obesity, metabolic syndrome, type 2 diabetes and cardiovascular disease are intimately related to chronic inflammation.A narrative review summarizing the most recent data of the literature describing the pathological implications of inflammation in obese patients with cardiometabolic disorders.Besides high ...
ESSER, Nathalie, Paquot, Nicolas, Scheen, André   +2 more
openaire   +2 more sources